AbbVie’s third successful Parkinson’s trial sets the stage for an eventful 2025
AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson’s disease on Monday and said ...
AbbVie's Parkinson's disease drug improves patient mobility in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...
Outsourcing-pharma6d
AbbVie’s Parkinson’s disease monotherapy achieves positive phase 3 results
“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...
AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal
Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's ...
AbbVie’s Phase III trial of Parkinson’s disease treatment meets primary endpoint
The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.
Betting Big On AbbVie: A Prescription For Growth And Dividends
AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...
Hope for Parkinson’s disease symptoms is found in late-stage drug study
Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...
The Pharma Letter6d
AbbVie Phase III success with tavapadon in Parkinson’s
US pharma major AbbVie announced positive top-line results from its pivotal Phase III TEMPO-2 trial evaluating ...
Crain's Chicago Business5d
After one disappointment, AbbVie gets good news out of Cerevel buy
The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...
Yahoo Finance6d
AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
Dec. 9, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in ...